University of Florida
University of Florida

Tag: Breathtec Biomedical

Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19

UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, announced that the external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the company to continue on with the Phase 3 part of the study.

Algernon Pharmaceuticals Lead Drug Ifenprodil Named As Potential COVID-19 Treatment in European Scientific Journal

Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, said that its lead drug candidate Ifenprodil was highlighted in a European scientific journal as a potential COVID-19 treatment.  In the January 5th edition of the European Archives of Psychiatry and Clinical Neuroscience, the authors of an independent research review identified Ifenprodil as a possible […]

Algernon Pharmaceuticals Finding New Uses for Safe, Older Drugs

Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, sat down with Proactive‘s Steve Darling at the 12th annual LD Micro Conference in Bel Air, California. The Vancouver, British Columbia-based company, is advancing its lead compounds for non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, […]

Algernon Pharmaceuticals Provides Update on Its Planned Phase II Clinical Trial

UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, provided an update to the market on its planned phase II clinical trial and its additional plans for 2020.      The company is focused on developing repurposed therapeutic drugs. Drug repurposing (also known as re-profiling, re-tasking or therapeutic switching) […]

Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56 Percent

Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, announced that NP-120, its repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), showed superiority in reducing fibrosis over two globally approved therapies for IPF, Pirfenidone and Nintedanib, in a well-established in vivo animal model study of IPF. Learn more about Algernon Pharmaceuticals’ […]

Breathtec Announces Name Change to Algernon Pharmaceuticals

UF startup Breathtec Biomedical Inc. is pleased to announce that as a result of the strength of the data from its Nash Pharmaceuticals pre-clinical research program, it will be changing its name to Algernon Pharmaceuticals Inc. The change will take place before the market opens on February 19, and the Company’s ticker symbol will change from […]

Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound in Second Pre-Clinical Study for Non-Alcoholic Fatty Liver Disease

Nash Pharmaceuticals Inc., a wholly owned subsidiary of UF startup Breathtec Biomedical Inc., announces that its lead compound for non-alcoholic steatohepatitis (NASH) NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM mouse model from SMC Laboratories. In addition, a second compound, NP-135 was identified as […]

Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease (Globe Newswire)

Nash Pharmaceuticals Inc., a wholly owned subsidiary of UF startup Breathtec Biomedical Inc., is pleased to announce that in a recent in vivo animal study for Crohn’s disease (CD), NP-178, its lead compound for the treatment of ulcerative colitis (UC), performed equivalent to and in some measurements, better than 5-ASA, a current global standard of […]